<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04408937</url>
  </required_header>
  <id_info>
    <org_study_id>CLJN452A2113</org_study_id>
    <nct_id>NCT04408937</nct_id>
  </id_info>
  <brief_title>The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.</brief_title>
  <official_title>A Randomized, Investigator and Subject Blinded, Multicenter, Parallel-arm Study to Determine the Safety and Tolerability of Tropifexor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether dosing tropifexor is safe and tolerable.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 13, 2020</start_date>
  <completion_date type="Anticipated">May 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in fasting circulating LDL-C levels after 2 weeks of tropifexor treatment</measure>
    <time_frame>week 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting circulating High density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) levels over 4 weeks of treatment</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ALT, AST and GGT over 4 weeks of treatment</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters include but not limited to Cmax (ng/ml) will be assessed in the domiciled patients</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters include but not limited to area under the curve (AUC) will be assessed in the domiciled patients</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>tropifexor A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LJN452/placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tropifexor B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo/LJN452</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triopifexor A</intervention_name>
    <description>LJN452/placebo</description>
    <arm_group_label>tropifexor A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tropifexor B</intervention_name>
    <description>placebo/LJN452</description>
    <arm_group_label>tropifexor B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Presence of Liver Disease

        Exclusion Criteria:

          -  Use of other investigational drugs at the time of enrollment, or within 5 half-lives
             of enrollment, or within 30 days, whichever is longer; or longer if required by local
             regulations.

          -  Subjects taking the following medicines UNLESS on a stable dose (within 25% of
             baseline dose) for at least 3 months before randomization:

        Type 1 diabetes and Uncontrolled Type 2 diabetes defined as HbAlc ≥ 9.5% at screening

        -Calculated eGFR ≤ 60 mL/min/1.73m2 (using the MDRD formula) Subjects with
        contraindications to MRI imaging.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tropifexor</keyword>
  <keyword>FXR agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

